



PUBLICATIONS BY THE PARKINSON STUDY GROUP

JOURNAL ARTICLES, LETTERS AND BOOK CHAPTERS

1. Shoulson I. Experimental therapeutics directed at the pathogenesis of Parkinson's disease. In DB Calne (Ed), Handbook of Experimental Pharmacology: Drugs for the treatment of Parkinson's disease. Berlin: Springer-Verlag. 1989 pp. 289-305.
2. Parkinson Study Group. DATATOP: A multicenter controlled clinical trial in early Parkinson's disease. *Arch Neurol* 1989;46:1052-1060.
3. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson's disease. *N Engl J Med* 1989;321:1364-1371.
4. Shoulson I and the Parkinson Study Group. Deprenyl and tocopherol antioxidative therapy of parkinsonism (DATATOP). *Acta Neurol Scand* 1989;(Suppl 126):171-175.
5. Shoulson I. Protective therapy for Parkinson's disease. In WC Koller and G Paulson (Eds), Therapy of Parkinson's Disease. NY: Marcel Dekker. 1990 pp. 357-368.
6. Shoulson I, Fahn S, Oakes D, Lang A, Langston JW, LeWitt P, Olanow W, Penney JB, Tanner C for the Parkinson Study Group. Deprenyl for the treatment of early Parkinson's disease (letter). *N Engl J Med* 1990;322:1527-1528.
7. Jankovic J, McDermott M, Carter J, Gauthier S, Goetz C, Golbe L, Huber S, Koller W, Olanow C, Shoulson I, Stern M, Tanner C, Weiner W, and the Parkinson Study Group. Variable expression of Parkinson's disease: A base-line analysis of the DATATOP cohort. *Neurology* 1990;40:1529-1534.
8. Shoulson I and the Parkinson Study Group. Effect of selegiline (l-deprenyl) on the progression of disability in early Parkinson's disease: A preliminary report. In UK Rinne, E Heinonen (Eds), Neuroprotective Therapy In Early Parkinson's Disease. Turku, Finland: Orion Corp, Farnos. 1991, pp. 25-32.
9. Parkinson Study Group. DATATOP and clinical neuromyology IX (special correspondence). *Neurology* 1991;41:771-773.
10. LeWitt PA and the Parkinson Study Group. Deprenyl's effect at slowing progression of parkinsonian disability: the DATATOP Study. *Acta Neurol Scand* 1991;84(Suppl 136):79-86.
11. Shoulson I. Estrategias terapeuticas en la enfermedad de Parkinson. *Arch de Neurobiol* 1991;54,6:277-281.

12. Shoulson I and the Parkinson Study Group. An interim report of the effect of selegiline (l-deprenyl) on the progression of disability in early Parkinson's disease. *Eur Neurol* 1992;32(Suppl 1):46-53.
13. LeWitt PA, Galloway MP, Matson W, Milbury P, McDermott M, Srivastava DK, Oakes D, and the Parkinson Study Group. Markers of dopamine metabolism in Parkinson's disease. *Neurology* 1992;42:2111-2117.
14. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. *N Engl J Med* 1993;328:176-183.
15. Shults CW and the Parkinson Study Group. Effect of selegiline (deprenyl) on the progression of disability in early Parkinson's disease. *Acta Neurol Scand* 1993;87(Suppl 146):36-42.
16. Parkinson Study Group. A controlled trial of lazabemide (RO19-6327) in untreated Parkinson's disease. *Ann Neurol* 1993;33:350-356.
17. Parkinson Study Group. A controlled trial of lazabemide (RO19-6327) in levodopa- treated Parkinson's disease. *Arch Neurol* 1994;51:342-347.
18. Kieburtz K, McDermott M, Como P, Growdon J, Brady J, Carter J, Huber S, Kanigan B, Landow E, Rudolph A, Saint-Cyr J, Stern Y, Tennis M, Thelen J, Shoulson I, and the Parkinson Study Group. The effect of deprenyl and tocopherol on cognitive performance in early untreated Parkinson's disease. *Neurology* 1994;44:1756-1759.
19. Parkinson Study Group (Fahn S, primary author). Cerebrospinal fluid homovanillic acid in the DATATOP study on Parkinson's disease. *Arch Neurol* 1995;52:237-245.
20. McDermott MP, Jankovic J, Carter J, Fahn S, Gauthier S, Goetz CG, Golbe LI, Koller W, Lang AE, Olanow CW, Shoulson I, Stern MB, Tanner CM, Weiner WJ, and the Parkinson Study Group. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. *Arch Neurol* 1995;52:565-570.
21. Parkinson Study Group (Shoulson I, primary author). Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP subjects not requiring levodopa. *Ann Neurol* 1996;39:29-36.
22. Parkinson Study Group (Penney J, primary author). Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. *Ann Neurol* 1996;39:37-45.
23. Parkinson Study Group (Kieburtz K, primary author). Effect of lazabemide on the progression of disability in early Parkinson's disease. *Ann Neurol* 1996;40:99-107.

24. LeWitt P, Oakes D, Cui L, and the Parkinson Study Group. The need for levodopa as an end point of Parkinson's disease progression in a clinical trial of selegiline and α -tocopherol. *Mov Disord* 1997;12:183-189.
25. Parkinson Study Group (Kieburtz K, primary author). Safety and efficacy of pramipexole in early Parkinson disease: A randomized dose-ranging study. *JAMA* 1997;278:125-130.
26. Richard IH, Kurlan R, and the Parkinson Study Group. A survey of antidepressant drug use in Parkinson's disease. *Neurology* 1997;49:1168-1170.
27. Parkinson Study Group (David Oakes, author). Letter to the Editor. Selegiline and excess mortality. *Clin Neuropharmacol* 1997;20:542.
28. Parkinson Study Group (Kieburtz K, primary author). Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. *Ann Neurol* 1997;42:747-755.
29. Richard IH, Kurlan R, Tanner C, Factor S, Hubble J, Suchowersky O, Waters C, and the Parkinson Study Group. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. *Neurology* 1997;48:1070-1077.
30. Carter JH, Stewart BJ, Archbold PG, Inoue I, et al, and the Parkinson Study Group. Living with a person who has Parkinson's disease: The spouse's perspective by stage of disease. *Mov Disord* 1998;13:20-28.
31. Parkinson Study Group (Shoulson I, primary author). Mortality in DATATOP: A multicenter trial in early Parkinson's disease. *Ann Neurol* 1998;43:318-325.
32. Shoulson I and the Parkinson Study Group. DATATOP: A decade of neuroprotective inquiry. *Ann Neurol* 1998;44(Suppl 1):S160-S166.
33. Vatassery GT, Fahn S, Kuskowski MA, and the Parkinson Study Group. Alpha tocopherol in CSF of subjects taking high-dose vitamin E in the DATATOP study. *Neurology* 1998;50:1900-1902.
34. Shoulson I and the Parkinson Study Group. DATATOP: A decade of neuroprotective inquiry. In: CW Olanow, P Jenner (Eds). Beyond the Decade of the Brain: Neuroprotection in Parkinson's Disease Volume 3. Kent, UK: Wells Medical Ltd. 1998 319-329.
35. Growdon JH, Kieburtz K, McDermott MP, Panisset M, Friedman JH, and the Parkinson Study Group. Levodopa improves motor function without impairing cognition in mild non-demented Parkinson's disease patients. *Neurology* 1998;50:1327-1331.
36. Parkinson Study Group (Friedman J, primary author). Low Dose Clozapine for the treatment of drug-induced psychosis in Parkinson's disease. *N Engl J Med* 1999;340:757-763.
37. Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. *Arch Neurol* 1999;56:529-535.

38. Shetty N, Friedman JH, Kieburtz K, Marshall FJ, Oakes D, and the Parkinson Study Group. The placebo response in Parkinson's disease. *Clin Neuropharmacol* 1999;22:207-212.
39. Parkinson Study Group (Schwid S, primary author). The impact of remacemide hydrochloride on levodopa concentrations in Parkinson's disease. *Clin Neuropharmacol* 1999;22:220-225.
40. Parkinson Study Group (Holloway R, primary author). A randomized controlled trial comparing pramipexole with levodopa in early Parkinson's disease: Design and methods of the CALM-PD study. *Clin Neuropharmacol* 2000;23:34-44.
41. Jankovic J, Rajput AH, McDermott MP, Perl DP, for the Parkinson Study Group. The evolution of diagnosis in early Parkinson disease. *Arch Neurol* 2000;57:369-372.
42. Parkinson Study Group (Schwid S, primary author). A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for PD. *Neurology*, 2000;54:1583-1588.
43. Parkinson Study Group (Holloway R, primary author). Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. *JAMA* 2000;284:1931-1938.
44. Parkinson Study Group (Marek K, primary author). A multicenter assessment of dopamine transporter imaging with DOPASCAN/SPECT in parkinsonism. *Neurology* 2000;55:1540-1547.
45. Factor SA, Friedman JH, Lannon MC, Oakes D, Bourgeois K and the Parkinson Study Group. Clozapine for the treatment of drug-induced psychosis in Parkinson's disease: Results of the 12 week open label extension in the PSYCLOPS trial. *Mov Disord* 2001;16:135-139.
46. Parkinson Study Group (Schwid S, primary author). A randomized, controlled trial of remacemide for motor fluctuations in Parkinson's disease. *Neurology* 2001;56:455-462.
47. Giladi N, McDermott MP, Fahn S, Przedborski S, Jankovic J, Stern M, Tanner C, and the Parkinson Study Group. Freezing of gait in PD: Prospective assessment in the DATATOP cohort. *Neurology* 2001;56:1712-1721.
48. Parkinson Study Group (de Marcaida JA, primary author). Evaluation of dyskinesias in a pilot, randomized, placebo-controlled trial of remacemide in advanced Parkinson disease. *Arch Neurol* 2001;58:1660-1668.
49. Goetz CG, Leurgans S, Raman R, and the Parkinson Study Group. Placebo-associated improvements in motor function: Comparison of subjective and objective sections of the UPDRS in early Parkinson's disease. *Mov Disord* 2002;17:283-288.
50. Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A, and the Parkinson Study Group. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. *Ann Neurol* 2002;51(5):604-12.

51. Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, Conneally PM, Foroud T, and the Parkinson Study Group. Genome screen to identify susceptibility genes for Parkinson disease in a sample without *parkin* mutations. *Am J Hum Genet* 2002;71:124-135.
52. Nichols WC, Pankratz N, Uniacke SK, Pauciulo MW, Halter C, Rudolph A, Conneally PM, Foroud T, and the Parkinson Study Group. Linkage stratification and mutation analysis at the *parkin* locus identifies mutation positive Parkinson's disease families. *J Med Genet* 2002;39:489-492.
53. Shults CW, Oakes D, Kiebertz K, Beal F, Hass R, Plumb S, Juncos JL, Nutt J, Shoulson I, Carter J, Kompoliti K, Perlmutter JS, Reich S, Stern M, Watts RL, Kurlan R, Molho E, Harrison M, Lew M, and the Parkinson Study Group. Effects of coenzyme Q₁₀ in early Parkinson disease: Evidence of slowing of the functional decline. *Arch Neurol* 2002;59:1541-1550.
54. Parkinson Study Group (Siderowf A, primary author). A controlled trial of rasagiline in early Parkinson disease: The TEMPO Study *Arch Neurol* 2002;59:1937-1943.
55. Parkinson Study Group (Marek K, primary author). Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. *JAMA* 2002;287(13):1653-1661.
56. Siderowf A, McDermott M, Kiebertz K, Blindauer K, Plumb S, Shoulson I, and the Parkinson Study Group. Test-retest reliability of the Unified Parkinson's Disease Rating Scale in patients with early Parkinson's disease: Results from a multicenter clinical trial. *Mov Disord* 2002;17(4):758-763.
57. Reider CR, Halter CA, Castelluccio PF, Oakes D, Nichols WC, Foroud T, and the Parkinson Study Group. Reliability of reported age at onset for Parkinson's disease. *Mov Disord*, 2003;18:275-279.
58. Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C, Shults C, Marder K, Conneally PM, Nichols WC, and the Parkinson Study Group. Heterozygosity for a mutation in the *parkin* gene leads to later onset Parkinson disease. *Neurology* 2003;60:796-801.
59. Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults C, Conneally PM, Foroud T, and the Parkinson Study Group. Significant linkage of Parkinson disease to chromosome 2q36-37. *Am J Hum Genet* 2003;72:1053-1057.
60. Welsh M, McDermott MP, Holloway RG, Plumb S, Pfeiffer R, Hubble J, and the Parkinson Study Group. Development and testing of the Parkinson's disease Quality of Life Scale. *Mov Disord* 2003;18(6):637-645.
61. Factor SA, Feustel PJ, Friedman JH, Comella CL, Goetz CG, Kurlan R, Parsa M, Pfeiffer R, and the Parkinson Study Group. Longitudinal outcome of Parkinson's disease patients with psychosis. *Neurology* 2003;60:1756-1761.

62. Pankratz N, Nichols WC, Uniacke SK, Halter C, Murrell J, Rudolph A, Shults CW, Conneally PM, Foroud T, and the Parkinson Study Group. Genome-wide linkage analysis and evidence of gene-by-gene interactions in a sample of 362 multiplex Parkinson disease families. *Hum Mol Genet* 2003;12:2599-2608.
63. Parkinson Study Group (Blindauer K. primary author). A controlled trial of rotigotine monotherapy in early Parkinson's disease. *Arch Neurol* 2003;60:1721-1728.
64. Nichols WC, Uniacke SK, Pankratz N, Reed T, Simon DK, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T, and the Parkinson Study Group. Evaluation of the role of Nurr1 in a large sample of familial Parkinson's disease. *Mov Disord* 2004;19(6):649-655.
65. Parkinson Study Group (Siderowf A. primary author). A controlled, randomized, delayed-start study of rasagiline in early Parkinson's disease. *Arch Neurol* 2004;61:561-566.
66. Marras C, Lang A, Krahn M, Tomlinson G, Naglie G, and the Parkinson Study Group. Quality of life in early Parkinson's disease: Impact of dyskinesias and motor fluctuations. *Mov Disord* 2004;19:22-28.
67. Parkinson Study Group. The safety and tolerability of a mixed lineage kinase inhibitor (CEP-1347) in PD. *Neurology* 2004;62:330-332.
68. Parkinson Study Group (Holloway RG, primary author). Pramipexole vs. levodopa as initial treatment for Parkinson disease: A 4-year randomized controlled trial. *Arch Neurol* 2004;61:1044-1053.
69. Pankratz N, Uniacke SK, Halter CA, Rudolph A, Shults CW, Conneally PM, Foroud T, Nichols WC, and the Parkinson Study Group. Genes influencing Parkinson disease onset: Replication of *PARK3* and identification of novel loci. *Neurology* 2004;62:1616-1618.
70. Noyes K, Dick AW, Holloway RG, and the Parkinson Study Group. Pramipexole v. levodopa as initial treatment for Parkinson's disease: A randomized clinical-economic trial. *Med Dec Making* 2004;24:472-485.
71. The Parkinson Study Group (Fahn S, primary author). Levodopa and the progression of Parkinson's disease. *N Engl J Med* 2004;351:2498-2508.
72. Marras C, Lang AE, Oakes D, McDermott MP, Kiebertz K, Shoulson I, Tanner CM, Fahn S, and the Parkinson Study Group. High dosage vitamin E supplementation and all-cause mortality. Letter to the Editor. *Annals of Int Med* 2005;143(2):152-153.
73. Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Rudolph A, Lang AE, and the Parkinson Study Group. Survival in Parkinson disease: Thirteen-year follow-up of the DATATOP cohort. *Neurology* 2005;64:87-93.
74. Parkinson Study Group (Schwid S, primary author). A randomized placebo-controlled trial of rasagiline in levodopa-treated Parkinson's disease patients with motor fluctuations (The PRESTO Study). *Arch Neurol* 2005;62:241-248.

75. Nichols WC, Pankratz N, Hernandez D, Paisan-Ruiz C, Jain S, Halter CA, Michaels VE, Reed T, Rudolph A, Shults CW, Singleton A, Foroud T, for the Parkinson Study Group-PROGENI investigators. Genetic screening for a single common *LRRK2* mutation in familial Parkinson's disease. *Lancet* 2005;365:410-412.
76. Siderowf A, Eberly S, Oakes D, Shoulson I on behalf of the Parkinson Study Group. Authors' response: Re-examination of the TEMPO study. *Arch Neurol* 2005;62(8):1320-1321.
77. Fahn S and the Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson's disease? *J Neurol* 2005;252(4):37-42.
78. Noyes K, Dick AW, Holloway RG and the Parkinson Study Group. Pramipexole and levodopa in early Parkinson's disease: Dynamic changes in cost effectiveness. *Pharmacoeconomics* 2005;23(12):1257-1270.
79. Pankratz N, Byder L, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T, Nichols WC and the Parkinson Study Group-PROGENI Investigators. Presence of an APOE4 allele results in significantly earlier onset of Parkinson's disease and a higher risk with dementia. *Mov Disord* 2006;21:45-49.
80. Parkinson Study Group (Blindauer K, primary author). Randomized placebo-controlled study of the nicotine agonist SIB-1508Y in Parkinson disease. *Neurology* 2006;66:408-410.
81. Parkinson Study Group (Blindauer K, primary author). A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. *Arch Neurol* 2006;63:210-216.
82. Biglan KM, Schwid S, Eberly S, Blindauer K, Fahn F, Goren T, Kieburtz K, Oakes D, Plumb S, Siderowf A, Stern M, Shoulson I and the Parkinson Study Group. Rasagiline improves quality of life in patients with early Parkinson's disease. *Mov Disord* 2006;21(5):616-623. [Rasagiline improves quality of life in patients wi...\[Mov Disord. 2006\] - PubMed Result](#)
83. Goetz CG, Schwid SR, Eberly SW, Oakes D, Shoulson I and the Parkinson Study Group TEMPO and PRESTO Investigators. Safety of rasagiline in elderly patients with Parkinson disease. *Neurology* 2006;66:1427-1429. [Safety of rasagiline in elderly patients with Parkinson disease -- Goetz et al. 66 \(9\): 1427 -- Neurology](#)
84. Elmer L, Schwid S, Eberly S, Goetz C, Fahn S, Kieburtz K, Oakes D, Blindauer K, Salzman P, Oren S, Prisco UL, Stern M, Shoulson I; Parkinson Study Group TEMPO and PRESTO Investigators. Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms. *J Neurol Sci* 2006;248(1-2):78-83. [Rasagiline-associated motor improvement in PD occu...\[J Neurol Sci. 2006\] - PubMed Result](#)
85. Holford NHG, Chan PLS, Nutt JG, Kieburtz K, Shoulson I and the Parkinson Study Group. Disease progression and pharmacodynamics in Parkinson disease – evidence for functional protection with levodopa and other treatments. *J of Pharmacokinetics and Pharmacodynamics* 2006;33(3):281-311. [Disease progression and pharmacodynamics in Parkin...\[J Pharmacokinet Pharmacodyn. 2006\] - PubMed Result](#)

86. deMarcaida JA, Schwid SR, White WB, Blindauer K, Fahn S, Kieburtz K, Stern M, Shoulson, I and the Parkinson Study Group TEMPO and PRESTO Tyramine Substudy Investigators and Coordinators. Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline. *Mov Disord* 2006;21(10):1716-1721. [Wiley InterScience :: Journal :: Article PDF](#)
87. Pankratz N, Pauciulo MW, Eisaesser VE, Marek DK, Halter CA, Rudolph A, Shults CW, Foroud T, Nichols WC and the Parkinson Study Group-PROGENI Investigators. Mutations in LRRK2 other than G2019S are rare in the North American-based sample of familial Parkinson disease. *Mov Disord* 2006;21:2257-2260. [Wiley InterScience :: Journal :: Article PDF](#)
88. Pankratz N, Pauciulo MW, Eisaesser VE, Marek DK, Halter CA, Wojcieszek J, Rudolph A, Shults CW, Foroud T, Nichols WC and the Parkinson Study Group-PROGENI Investigators. Mutations in DJ-1 are rare in familial Parkinson disease. *Neuroscience Letters* 2006;408(3):209-213. [Mutations in DJ-1 are rare in familial Parkinson d...\[Neurosci Lett. 2006\] - PubMed Result](#)
89. Ishihara L, Warren L, Gibson R, Amouri R, Lesage S, Durr A, Tazir M, Wszolek ZK, Uitti RJ, Nichols WC, Friggith A, Hattori N, Leppert D, Watts R, Zabetian CP, Foroud T M, Farrer MJ, Brice A, Middleton L, Hentati F. Clinical Features of Parkinson Disease Patients with Homozygous Leucine-Rich Repeat Kinase 2 G2019S Mutations. *Arch Neuro* 2006;63(9):1250-1254. [Clinical features of Parkinson disease patients wi...\[Arch Neurol. 2006\] - PubMed Result](#)
90. Nichols WC, Marek DK, Pauciulo MW, Pankratz N, Halter C, Rudolph A, Shults C, Wojcieszek J, Foroud T and the Parkinson Study Group-PROGENI Investigators. R1514Q substitution in LRRK2 is not a pathogenic Parkinson's disease mutation. *Mov Disord* 2007;22:254-257. [Wiley InterScience :: Journal :: Article PDF](#)
91. Nichols WC, Eisaesser VE, Pankratz N, Pauciulo MW, Marek DK, Halter C, Rudolph A, Shults CW, Foroud T and the Parkinson Study Group-PROGENI Investigators. LRRK2 mutation analysis in Parkinson disease families with evidence of linkage to PARK8. *Neurology* 2007;69:1737-1744 [LRRK2 mutation analysis in Parkinson disease famil...\[Neurology. 2007\] - PubMed Result](#)
92. Parkinson Study Group (Tanner CM, primary author). Pramipexole in levodopa-treated Parkinson disease patients of African, Asian and Hispanic heritage. *Clinical Neuropharmacology* 2007;30(2):72-85 [Pramipexole in levodopa-treated Parkinson disease ...\[Clin Neuropharmacol. 2007 Mar-Apr\] - PubMed Result](#)
93. Constantinescu R, Romer M, Kieburtz K. Malignant melanoma in early Parkinson's disease: The DATATOP trial. *Mov Disord* 2007;22(5):720-722. [Wiley InterScience :: Journal :: Article PDF](#)
94. Constantinescu R, Romer M, McDermott M, Kamp C, Kieburtz K and the Parkinson Study Group-CALM-PD Investigators. Impact of pramipexole on the onset of levodopa related

- dyskinesias. *Mov Disord* 2007;22(9):1317-1319. [Wiley InterScience :: Journal :: Article PDF](#)
95. Biglan KM, Holloway RG, McDermott MP, Richard IH and the Parkinson Study Group-CALM-PD Investigators. Risk factors for somnolence, edema, and hallucinations in early Parkinson disease. *Neurology* 2007;69:187-195. [Risk factors for somnolence, edema, and hallucinat...\[Neurology. 2007\] - PubMed Result](#)
 96. Hauser RA, McDermott MP, Messing S and the Parkinson Study Group-CALM-PD Investigators. Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease. *Arch Neurol* 2007;63:1756-1760 [Factors associated with the development of motor f...\[Arch Neurol. 2006\] - PubMed Result](#)
 97. Marras C, McDermott MP, Rochon PA, Tanner CM, Naglie G, Lang AE, and the Parkinson Study Group DATATOP Investigators. Predictors of Deterioration in Health-Related Quality of Life in Parkinson's Disease: Results from the DATATOP Trial. *Movement Disorders* 2008;23(5):653-659. [Wiley InterScience :: Journal :: Article PDF](#)
 98. Goetz CG, Wu J, McDermott MP, Adler CH, Fahn S, Freed CR, Hauser RA, Olanow WC, Shoulson I, Tandon PK, Parkinson Study Group, and Leurgans S. Placebo Response in Parkinson's Disease: Comparisons Among 11 Trials Covering Medical and Surgical Interventions. *Movement Disorders* 2008;23(5):690-699. [Wiley InterScience :: Journal :: Article PDF](#)
 99. Schwarzschild MA, Schwid SR, Marek K, Watts A, Lang AE, Oakes D, Shoulson I, Ascherio A and the Parkinson Study Group PRECEPT Investigators. Serum Urate as a Predictor of Clinical and Radiographic Progression in Parkinson Disease. *Arch Neurol.* 2008;65(6):716-723. <http://archneur.ama-assn.org/cgi/reprint/65/6/716.pdf>
 100. White WB, Salzman P, Schwid SR; for the Parkinson's Rasagiline: Efficacy and Safety in the Treatment of "Off" Parkinson Study Group. Transtelephonic Home Blood Pressure to Assess the Monoamine Oxidase-B Inhibitor Rasagiline in Parkinson Disease. *Hypertension.* 2008;52:587-593. <http://hyper.ahajournals.org/cgi/reprint/52/3/587.pdf>
 101. Schifitto G, Friedman JH, Oakes D, Shulman L, Comella CL, Marek K, Fahn S; Parkinson Study Group ELLDOPA Investigators. Fatigue in levodopa-naïve subjects with Parkinson disease. *Neurology* 2008;71(7):481-485. [Fatigue in levodopa-naive subjects with Parkinson ...\[Neurology. 2008\] - PubMed Result](#)
 102. Pankratz N, Marder KS, Halter CA, Rudolph A, Shults CW, Nichols WC, Foroud T; Parkinson's Study Group-PROGENI Investigators. Clinical correlates of depressive symptoms in familial Parkinson's disease. *Mov Disord.* 2008 Nov 15;23(15):2216-23. [Wiley InterScience :: Journal :: Article PDF](#)
 103. Nichols WC, Pankratz N, Marek DK, Pauciulo MW, Elsaesser VE, Halter CA, Rudolph A, Wojcieszek J, Pfeiffer RF, Foroud T, PSG-PROGENI Investigators. Mutations in *GBA* are associated with familial Parkinson disease susceptibility and age of onset. *Neurology* 2009; 72(4):310-316. [PMID 18987351](#)

104. Biglan, K, Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. *Arch Neurol*, Vol. 66 (5):563-570. Published online March 9, 2009;66(5):(doi:10.1001/archneurol.2009.32); download available May 2009 www.archneurol.com.
105. Pontone GM, Williams JR, Anderson KE, Chase G, Goldstein SA, Grill S, Hirsch ES, Lehmann S, Little JT, Margolis RL, Rabins PV, Weiss HD, Marsh L. Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease. *Mov Disord* 2009;24(9):1333-1338.
106. Uc EY, McDermott MP, Marder KM, Anderson SW, Litvan I, Como PG, Auinger P, Chou KL, Growdon JC, PSG DATATOP Investigators. Incidence of and risk factors for cognitive impairment in an early Parkinson disease clinical trial cohort. *Neurology* 2009;73:1469-1477.
107. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Genetic determinants of hair color and Parkinson's disease risk. *Ann Neurol* 2009;65:76-82.
108. Pankratz N, Kissell DK, Pauciulo MW, Halter CA, Rudolph A, Pfeiffer RF, Marder KS, Foroud T, Nichols WC and Parkinson Study Group PROGENI Investigators. Parkin dosage mutations have greater pathogenicity in familial PD than simple sequence mutations. *Neurology* 2009;73:279-286.
109. Pankratz N, Nichols WC, Elsaesser VE, Pauciulo MW, Marek DK, Halter CA, Wojcieszek J, Rudolph A, Pfeiffer RF, Foroud T and Parkinson Study Group PROGENI Investigators. Alpha-Synuclein and Familial Parkinson's Disease. *Mov Disord* 2009;24(8):1125-1131.
110. Ravina B, Tanner C, Dieulliis D, Eberly S, Flagg E, Galpern WR, Fahn S, Goetz CG, Grate S, Kurlan R, Lang AE, Marek K, Kiebertz K, Oakes D, Elliott R, Shoulson I; Parkinson Study Group LABS-PD Investigators. A longitudinal program for biomarker development in Parkinson's disease: a feasibility study. *Mov Disord*. 2009 Oct 30;24(14):2081-90. <http://www3.interscience.wiley.com/cgi-bin/fulltext/122559005/PDFSTART>
111. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. Family history of melanoma and Parkinson disease risk. *Neurology* 2009;73:1286-1291. <http://www.neurology.org/cgi/content/full/73/16/1286>
112. Ascherio A, LeWitt PA, Xu K, Eberly S, Watts A, Matson WR, Marras C, Kiebertz K, Rudolph A, Bogdanov MB, Schwid SR, Tennis M, Tanner CM, Beal F, Lang AE, Oakes D, Fahn S, Shoulson I, Schwarzschild MA, Parkinson Study Group DATATOP Investigators. Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease. *Arch Neurol*. 2009;66(12):E1-E9. Download a copy via: <http://archneur.ama-assn.org/cgi/reprint/2009.247?ijkey=0Yff1Zb1APdCYGu&keytype=finite>.
113. Huang P, Goetz CG, Woolson RF, Tilley B, Kerr D, Palesch Y, Elm J, Ravina B, Bergmann KJ, Kiebertz K, and The Parkinson Study Group. Using Global Statistical Tests in Long-Term Parkinson's Disease Clinical Trials. *Mov Disord* 2009;24(12):1732-1739.

114. Marras C, Lang AE, Eberly SW, Oakes D, Fahn S, Schwid SR, Hyson C, Shoulson I, on behalf of the Parkinson Study Group DATATOP and PRECEPT investigators. A comparison of treatment thresholds in two large Parkinson's disease clinical trial cohorts. *Mov Disord* 2009;24(16):2370-2378. <http://www3.interscience.wiley.com/cgi-bin/fulltext/122682539/PDFSTART>
115. Hauser RA, Auinger P, Oakes D, on behalf of the Parkinson Study Group. Levodopa response in early Parkinson's disease. *Mov Disord* 2009;24(16):2328-2336. <http://www3.interscience.wiley.com/cgi-bin/fulltext/122682497/PDFSTART>

ABSTRACTS

116. Shoulson I and the Parkinson Study Group - Fahn S, Brin M, Burke R, Bressman S, Tetrud J, Langston JW, Jankovic J, Kurlan R, Plumb S, Odoroff C, Tanner C, Goetz C, Klawans H, Shannon K, Lang A, Weiner W, Sanchez-Ramos J, Penney J, Young A, Starosta-Rubinstein S, Hurtig H, Stern M, Gollomp S, Pfeiffer R, Friedman J, Olanow W, Paulson G, Tsui J, Nutt J, Rodnitzky R, Grimes D, Hassan M, LeWitt P, Hoehn M, Bennett J. Correlates of clinical decline in early Parkinson's disease. *Neurology* 1987; 37 (Suppl 1):278.
117. Shoulson I and the Parkinson Study Group. Antioxidative experimental strategies for Parkinson's disease (abstract). 9th International Symposium on Parkinson's Disease, Jerusalem, Israel, June 5-9, 1988, p. 19.
118. Shoulson I and the Parkinson Study Group. Antioxidative experimental strategies aimed at slowing the progression of Parkinson's disease (abstract). *Proceedings of the International Symposium on Alzheimer's Disease*, June 12-15, 1988, Kuopio, Finland (World Federation of Neurology Research Group on Dementia) Publications of the University of Kuopio (ISBN 951-780-488-1), 1988; pp. 35-36.
119. Kurlan R, Clark S, Penney J, Shoulson I. Economic impact of successful protective therapy for Parkinson's disease *Ann Neurol* 1988; 24:153.
120. Shoulson I and the Parkinson Study Group. Deprenyl in early Parkinson's disease: symptomatic versus protective efficacy (abstract). *Neurology* (Suppl. 1) 1990; 40:153.
121. Oakes D and the Parkinson Study Group. Progression of early Parkinson's disease until levodopa therapy is required (abstract). *Neurology* (Suppl. 1) 1990; 40:370.
122. Environmental Influences Working Group of the Parkinson Study Group and The Parkinson Study Group (CM Tanner, Presenter, Chicago, IL). Smoking and Age at Onset of Parkinson's Disease: Analysis of the DATATOP Cohort (abstract). *Ann Neurol* 1990; 28:295.
123. The Parkinson Study Group (PG Como, Presenter, Rochester, NY). Effect of Deprenyl on Neuropsychological Function in Early Parkinson's Disease (abstract). *Ann Neurol* 1990; 28:297.
124. Hall WJ, Oakes D and the Parkinson Study Group. Statistical issues in monitoring a 2 x 2 factorial clinical trial (abstract). *Controlled Clin Trials* 1990; 11:264.
125. Oakes D, McDermott M, Eberly S, Plumb S, Watts A, Shoulson I and the Parkinson Study Group. Investigator effects in a multicenter trial for Parkinson's disease (abstract). *Controlled Clin Trials* 1990; 11:284.
126. Pelusio RM, Rudolph A, Orme C, Evans P, Plumb S, Oakes D, Shoulson I and the Parkinson Study Group. DATATOP: Managing an accelerated trial (abstract). *Controlled Clin Trials* 1990; 11:304.
127. Kieburtz K, Como P, McDermott M, Rudolph A, Growdon JJ, Tennis M, Brady J, Kanigan B, Saint-Cyr JA, Kierans C, Landow E, Stern Y, Thelen J and the Parkinson Study Group.

- Neuropsychological evaluation in early untreated Parkinson's disease (abstract). *Ann Neurol* 1990; 28:236.
128. LeWitt PA, Galloway M, Oakes D, Watts A, Mattson W and the Parkinson Study Group. Homovanillic acid, other monoamine metabolites, and xanthine in parkinsonian CSF. *Neurology* 1991; 41 (Suppl 1): 379.
 129. Pelusio RM, Miller C, Orme C, Andrews M, Casaceli C, Lieou J, Kieburtz K, Wixsom J, Shoulson I, and the Parkinson Study Group. Use of Computer Applications to Facilitate Retroactive Updates to a Database. *Controlled Clin Trials* 1991; 12:707.
 130. LeWitt P, Galloway M, Matson W, McDermott M, Oakes D, and the Parkinson Study Group. Markers of endogenous dopamine synthesis in Parkinson's disease. *Neurology* 1992; 42 (Suppl 3):421.
 131. Pelusio RM, Wixsom J, Rudolph A, Orme C, Shoulson I, and the Parkinson Study Group. Subject file checklists to facilitate clinical trial closeout activities. *Controlled Clin Trials* 1992; 13:438.
 132. LeWitt P, Galloway M, Matson W, Milbury P, McDermott M, Oakes D, the Parkinson Study Group. CSF studies in untreated Parkinson disease: dopamine metabolism and xanthine. *Neurosci Abstracts* 1992; 18:1248.
 133. Parkinson Study Group. Assessment of short-term tolerability of lazabemide (Ro 19-6327) in untreated Parkinson's disease. *Mov Disord* 1992; 7 (Suppl 1):14.
 134. McDermott MP, Jankovic J and the Parkinson Study Group. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. *Neurology* 1992; 42 (Suppl 3):441.
 135. Fink JS, Shalish C, Hotamosligil G, Rould E, Sullivan J, Growdon J, LeWitt P, Breakefield XO, the Parkinson Study Group. Allelic variations in the MAO-A and MAO-B genes in Parkinson disease. *Mov Disord* 1992; 7:289-290.
 136. LeWitt PA, Bannon M, Galloway M, Kapatos G, Matson W, McDermott M, Oakes D and the Parkinson Study Group. Monoaminergic metabolism, substance P, met-enkephalin, and biopterin metabolism in Parkinson's disease. *Neurol* 1993; 43:A408.
 137. Rudolph A, Pelusio RM, McManus J, Bordwell KL, Kieburtz K, Dorflinger E, Shoulson I and the Parkinson Study Group. Promoting enrollment in a multi-center clinical trial. *Controlled Clin Trials* 1993; 14:438.
 138. Pelusio RM, Casaceli CJ, Orme C, Connorton J and the Parkinson Study Group. Monitoring completion of data form discrepancies. *Controlled Clin Trials* 1993;14:429.
 139. Penney JB and the Parkinson Study Group. Effect of sustained deprenyl and tocopherol therapy in levodopa-treated parkinsonian patients. *Annals Neurol* 1993; 34:247.

140. Shoulson I and the Parkinson Study Group. The impact of extended deprenyl treatment in patients not requiring levodopa therapy. *Annals Neurol* 1993; 34:263.
141. Parkinson Study Group (S Fahn, primary author). The DATATOP study: cerebrospinal fluid homovanillic acid changes in patients with mild, early parkinsonism. *Mov Disord* 1993; 8:410-411.
142. Parkinson Study Group (K Kieburtz, primary author). Controlled trial of lazabemide in levodopa-treated Parkinson's disease. *Mov Disord* 1993; 8:411.
143. Hyland K, Bottiglieri T, Engle T, LeWitt PA, the Parkinson Study Group. Pteridine and S-adenosylmethionine concentrations in CSF from unmedicated parkinsonians and controls. *Neurology* 1994; 44 (suppl 2):A154.
144. Casaceli C, Sotack J, Orme C, Rudolph A, Kieburtz K and the Parkinson Study Group. Electronic events coding. *Controlled Clin Trials* 1994; 15:89.
145. Orme C, Casaceli C, Randolph H, Rudolph A and the Parkinson Study Group. Verification and tracking of records in a clinical trial database. *Controlled Clin Trials* 1994; 15:92.
146. LeWitt P, Aizenman E, Newcomer T, Loeffler D and the Parkinson Study Group. The search for an endogenous neurotoxin in Parkinson's disease: TOPA and TOPA-quinone. *Mov Disord* 1994; 9:482.
147. LeWitt P, Oakes D, Cui L, and the Parkinson Study Group. Endpoints for the study of Parkinson's disease progression. *Mov Disord* 1994; 9:480.
148. Parkinson Study Group (Kieburtz K, primary author). Effect of lazabemide on the progression of disability in early Parkinson's disease. *Neurology* 199;545 (Suppl 45):A291.
149. Pelusio RM, Casaceli C, and the Parkinson Study Group. An electronic interface for reporting and tracking significant clinical events. *Controlled Clin Trials* 1995; 16:112-113S.
150. Parkinson Study Group (Kieburtz K, primary author). Dose Ranging Study of the Safety and Efficacy of the Dopamine Agonist Pramipexole in Early Parkinson's Disease. *Mov Disord* 1995; 10:691.
151. Richard I, Kurlan R, Tanner C, the Parkinson Study Group. Serotonin syndrome and the combined use of deprenyl and an antidepressant in Parkinson's disease. *Neurology* 1996; 46:A374.
152. Giladi N, McDermott M, Fahn S, Przedborski S and the Parkinson Study Group. Freezing of gait in Parkinson's disease. *Neurology* 1996;46:A377.
153. Giladi N, McDermott M, Fahn S, Przedborski S, The Parkinson Study Group. Freezing of gait in Parkinson's disease. *Mov Disord* 1996;11:167.
154. Parkinson Study Group (Kieburtz K, primary author). The COMT inhibitor entacapone improves parkinsonian features in fluctuating patients. *Mov Disord* 1996; 11:268.

155. Parkinson Study Group (Kieburtz K, primary author) and Nordic Study Group (NOMECOMT) (Rinne UK, primary author). The COMT inhibitor entacapone increases "on" time in levodopa-treated PD patients with motor fluctuations: report of two randomized, placebo-controlled trials. *Mov Disord* 1996; 11:595.
156. Fahn S, Rudolph A and the Parkinson Study Group. Neurologists' treatment patterns for Parkinson's disease. *Mov Disord* 1996; 11:595.
157. Growdon JH, Kieburtz K, McDermott, M, Panisset M, Friedman JH and the Parkinson Study Group. Levodopa improves motor function without impairing cognition in mild non-demented PD patients. *Mov Disord* 1997; 12:57.
158. Parkinson Study Group (Marek K, primary author). DOPASCAN and SPECT is a sensitive and specific diagnostic tool for parkinsonism. *Mov Disord* 1997; 12:835.
159. Panisset M, Siderowf A, McDermott M, Kieburtz K, Friedman J, Growdon J and the Parkinson Study Group. Baseline predictors of subsequent dementia in the DATATOP cohort. *Mov Disord* 1997; 12:836.
160. Welsh M, McDermott M, Holloway R, Plumb S, Pfeiffer R, Hubble J (Parkinson Study Group Quality of Life Task Force). Development and testing of the Parkinson's disease quality of life scale: the PDQUALIF. *Mov Disord* 1997; 12:836.
161. Parkinson Study Group (Shoulson I, primary author). Clinical outcome following placebo-controlled withdrawal of deprenyl (selegiline) among levodopa-treated DATATOP subjects. *Mov Disord* 1997; 12:838.
162. Carter JH, Stewart BJ, Archbold PG, Inoue I, the Parkinson Study Group. Living with a person who has Parkinson's disease: the spouse's perspective by stage of disease. *Neurology* 1997; 48:A180.
163. Rajput AM, Jankovic J, McDermott M, and the Parkinson Study Group. Diagnostic accuracy in early Parkinson's disease. *Neurology* 1997; 47:A369.
164. Parkinson Study Group (Friedman J, primary author). Low dose clozapine for the treatment of drug-induced psychosis (DIP) in idiopathic Parkinson's disease (PD): Results of the double-blind, placebo-controlled PSYCLOPS trial. *Neurology*, 1998; 50:A70.
165. Factor SA and the Parkinson Study Group. Clozapine for the treatment of drug induced psychosis in Parkinson's disease: results of the 12 week open label follow up in the PSYCLOPS trial (abstract). *Mov Disord* 1998;13(suppl 2):241.
166. Tanner CM and the Parkinson Study Group. Pramipexole in ethnic minorities with Parkinson's disease (PD): safety, tolerability, and efficacy (PRIME) (abstract). *Mov Disord* 1999;14:901.

167. Holloway R, McDermott M, Kieburtz K, Penney J, Fahn S, Lang AE, Shoulson I and the Parkinson Study Group. Estimating the incidence of motor complications in patients starting levodopa: implications for clinical trials. *Mov Disord* 1999;14:905.
168. Marsa M, Friedman J, Oakes D, Greenaway H and the Parkinson Study Group. Phenomenology of Levodopa-Induced Psychosis in Parkinson's Disease. Congress of the International Psychogeriatric Association, August 15-20, 1999, Vancouver, BC, Canada, abstract booklet, p.137.
169. Seibyl J, and the Parkinson Study Group. Multicenter quantitative SPECT evaluation of the dopamine transporter ligand DOPASCAN as a diagnostic marker of Parkinson's disease. *J Nuclear Med*, submitted.
170. Parkinson Study Group (Schwid S, primary author). The glutamate antagonist remacemide improves motor performance in levodopa-treated Parkinson's disease. *Neurology* 1999; 52:A262.
171. Holloway RG, The Parkinson Study Group. Pramipexole versus levodopa in early Parkinson's disease: a randomized clinical trial. *Neurology* 2000; 54 (Suppl 3):A89.
172. Parkinson Study Group (Kenneth Marek, primary author). β -CIT-SPECT assessment of progression of Parkinson's disease in subjects participating in the CALM-PD study (abstract). *Neurology* 2000; 54:A90.
173. Blindauer K and the Parkinson Study Group. Double-blind, placebo-controlled, dose-ranging study of the safety and tolerability of SIB-1508Y, a nicotinic receptor agonist, in early Parkinson's disease patients. *Neurology*, 2000;54:A278.
174. Siderowf A and the Parkinson Study Group. Test-retest reliability of the unified Parkinson's disease rating scale: Results from a multicenter clinical trial. *Neurology* 2000;54:A373.
175. Kieburtz K, Reinikainen K, Gordin A and the Nomecomt and Parkinson Study Group. Effect of entacapone on quality of life related assessments in Parkinson's disease. *Mov Disord* 15 2000;(suppl 3):135.
176. Parkinson Study Group (Goetz G, primary author). Placebo-related improvements in motor function in early Parkinson's disease. *Ann Neurol* 2000;48:433.
177. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson's disease. *Ann Neurol* 2000;48:489.
178. Parkinson Study Group (K Marek, presenter). Comparison of imaging and clinical endpoints in subjects participating in the CALM-PD study. *Neurology* 2001;56:A73.
179. Parkinson Study Group (K Blindauer, presenter). Tyramine challenge to assess the safety of rasagiline monotherapy in a placebo-controlled multicenter trial for early Parkinson's disease (the TEMPO study). *Neurology* 2001;56:A345.

180. Parkinson Study Group (S Fahn, presenter). Rotigotine transdermal SysTem (SPM-962) is safe and effective as monotherapy in early Parkinson's disease (PD) (abstract). XIV Int'l Congress on Parkinson's Disease, July 27-August 4, 2001, Helsinki, Finland, in *Parkinsonism & Related Disorder*, J WFN Research Committee on Parkinsonism and Related Disorders.
181. Parkinson Study Group (K Kieburtz, presenter). Efficacy and safety of rasagiline as monotherapy in early Parkinson's disease (abstract). XIV Int'l Congress on Parkinson's Disease, July 27-August 4, 2001, Helsinki, Finland, in *Parkinsonism & Related Disorder*, J WFN Research Committee on Parkinsonism and Related Disorders.
182. Parkinson Study Group (K Kieburtz, presenter). Dopamine agonists in the prevention and treatment of motor complications: CALM-PD. XIV Int'l Congress on Parkinson's Disease, July 27-August 4, 2001, Helsinki, Finland, in *Parkinsonism & Related Disorder*, J WFN Research Committee on Parkinsonism and Related Disorders.
183. Parkinson Study Group (A Siderowf, presenter). Earlier treatment with rasagiline may attenuate (UPDRS) progression of PD. *Mov Disord* 2001;16:981.
184. Parkinson Study Group (KA Blindauer, presenter). Defining responder status in a clinical trial of the rotigotine transdermal system (SPM-962) in early Parkinson's disease. *Mov Disord* 2001;16:981-982.
185. Noyes K, Zwanziger J, Dick AW, Holloway R and the Parkinson Study Group. Do dopaminergic complications predict quality of life in Parkinson's disease? *Mov Disord* 2001;16:988.
186. Parkinson Study Group (JA deMarcaida, presenter). Current opinions on appropriate endpoints in Parkinson's disease-modifying trials. *Mov Disord* 2001;16:989-990.
187. Reider CR, Halter CA, Foroud T, Oakes D, and the Parkinson's Study Group. Reliability of self-reporting age of onset for Parkinson's disease. *Mov Disord* 2001;16:991-992.
188. Parkinson Study Group (RG Holloway, presenter). Pramipexole versus levodopa as initial treatment for Parkinson disease: A four-year randomized controlled trial. *Neurology* 2002 58 (Suppl 3): A81-82.
189. Marek KL and the Parkinson Study Group. Pramipexole versus levodopa: effects on Parkinson disease progression assessed by dopamine transporter imaging. *Neurology* 2002;58 (Suppl 3): A82.
190. Reider C, Halter C, Castelluccio P, Foroud T, and the Parkinson Study Group. Differences in duration from Parkinsonian symptom onset to diagnosis among concordantly affected siblings. *Neurology* 2002 58 (Suppl 3): A108.
191. Pankratz ND, Nichols WC, Uniacke SK, Rudolph A, Halter C, Shults C, Conneally PM, Foroud T, and the Parkinson Study Group. Genome screen to identify loci contributing to the susceptibility for Parkinson's disease. *Neurology* 2002 58(Suppl 3): A111.

192. Nichols WC, Pankratz ND, Uniacke SK, Pauciulo MW, Halter C, Rudolph A, Conneally PM, Foroud T, and the Parkinson Study Group. Stratification by linkage rather than age of onset identifies more *Parkin* mutation positive, PD families. *Neurology* 2002;58 (Suppl 3): A409-410.
193. Parkinson Study Group (S. Schwid, presenter). CEP-1347 in Parkinson disease: A pilot study. *Mov Disord* 2002;17(Suppl. 5):S91.
194. Parkinson Study Group (S. Schwid, presenter). Rasagiline improves quality of life in patients with early Parkinson's disease. *Mov Disord* 2002;17(Suppl. 5):S92.
195. Parkinson Study Group (PLS Chan, presenter). Application of clinical trial simulation to evaluate the ELLDOPA trial design. *Mov Disord* 2002;17(Suppl. 5):S111.
196. Parkinson Study Group (K. Marek, presenter). Assessment of CEP-1347 Interaction with β -CIT Striatal Uptake in Parkinson's Disease. *Mov Disord* 2002;17(Suppl. 5):S167.
197. Friedman JH, Messing S, Oakes D, Breier A, Feldman PD and The Parkinson Study Group. A descriptive and comparative analysis of psychotic symptoms in three placebo controlled double blinded trials of atypical antipsychotic drugs in the treatment of drug induced psychosis in Parkinson's disease. *Mov Disord* 2002;17:1105.
198. Factor SA, Feustel PJ, Friedman JH, Comella, Goetz CG, Kurlan R, Parsa M, Pfeiffer R and The Parkinson Study Group. Longitudinal outcome of PD patients with psychosis: persistence of behavioral impairments, mortality and nursing home placement. *Mov Disord* 2002;17:1105.
199. Biglan KM, Holloway RG, Shoulson I and the Parkinson Study Group. An item analysis of the mental unified Parkinson disease rating scale (UPDRS) in individuals with early Parkinson's disease (PD) treated initially with pramipexole vs. levodopa: A sub analysis of the 4-year CALM-PD trial. *Mov Disord* 2002;17:1107.
200. Biglan KM, Holloway RG, Shoulson I and the Parkinson Study Group. An item analysis of the mental unified Parkinson disease rating scale (UPDRS) in individuals with early Parkinson's disease (PD) treated initially with pramipexole vs. levodopa: A sub analysis of the 4-year CALM-PD trial. *Mov Disord* 2002;17(5):S114.
201. Foroud T, Uniacke SK, Liu L, Pankratz N, Rudolph A, Halter C, Shults C, Conneally PM, Nichols WC, and the Parkinson Study Group. Identification and characterization of *Parkin* mutation among later-onset familial Parkinson's disease subjects. *Ann Neurol* 2002;52:3 (Suppl 1):S37.
202. Parkinson Study Group (S. Fahn, presenter) Results of the ELLDOPA (earlier vs. later levodopa) study. *Mov Disord* 2002;17 (Suppl 5):S13.
203. Marek KL, Seibyl J, Jennings D, Parkinson Study Group. Pramipexole versus levodopa: 5-year follow-up of Parkinson disease progression assessed by dopamine transporter imaging in the CALM-PD CIT study. *Neurology* 2003;60:A293.

204. Marek KL, Seibyl J, Parkinson Study Group. β -CIT scans without evidence of dopaminergic deficit (SWEDD) in the ELLDOPA-CIT and CALM-CIT study: long-term imaging. *Neurology* 2003;160:293.
205. Parkinson Study Group (K Blindauer, presenter) Delayed response to levodopa and response failures account for a large percentage of daily off time in advanced Parkinson's disease patients with motor fluctuations. *Neurology* 2003;60:A81-82.
206. Parkinson Study Group (S Fahn, presenter) Does levodopa slow or hasten the rate of progression of Parkinson disease? The results of the ELLDOPA trial. *Neurology* 2003;60:A80-81.
207. Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T, Parkinson Study Group. PARK3 and PARK7 linked to age of onset of Parkinson disease. *Neurology* 2003;60(Suppl 1):A127.
208. Nichols WC, Pankratz N, Uniacke SK, Reed T, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud TM, and the Parkinson Study Group. Lack of association of homozygosity for the 7048G7049 intron six nurr1 gene polymorphism in 322 families with Parkinson disease. *Neurology* 2003;60(Suppl 1):A 281-282.
209. Parkinson Study Group (CM Tanner, presenter). Pilot study to develop a method for long term follow-up of persons with neurologic diseases (FOUND). *Mov Disord* 2003;18(9):1082.
210. Schwarzschild MA, Chen J-F, Tennis M, Messing S, Kamp C, Ascherio A, Holloway RG, Marek K, Tanner CM, McDermott M, Lang AE, Parkinson Study Group. Relating caffeine consumption to Parkinson's disease progression and dyskinesias development. *Mov Disord* 2003;18(9):1082-1083.
211. Fahn S, Parkinson Study Group. Evaluation of the long-duration benefit from levodopa: Results from the ELLDOPA (Earlier vs. Later LevoDOPA) Study. *Mov Disord* 2003;18(9):1085-1086.
212. Parkinson Study Group, Stern M. A controlled trial of rasagiline in Parkinson's disease patients with levodopa-related motor fluctuations (PRESTO Study). *Ann Neurol* 2003;54(7):S27.
213. Noyes K, Dick AW, Holloway RG, and Parkinson Study Group. Cost-effectiveness analysis of pramipexole in early Parkinson's disease. *Value in Health*;2003;6(3):274.
214. Pankratz N, Nichols WC, Uniacke SK, Halter C, Rudolph A, Shults CW, Conneally PM, Foroud T, Parkinson Study Group. Evidence for a gene on chromosome 10 that influences both PD and AD susceptibility. *Neurol* 2004;62 (Suppl 5):A27.
215. Biglan KM, Holloway RG, McDermott MP, Richard IH, Parkinson Study Group. Predicting incident non-motor complications of dopaminergic therapy in patients with early Parkinson's disease: A secondary analysis of the CALM-PD trial. *Mov Disord* 2004;19 (Suppl 9):S205.

216. Parkinson Study Group (Elmer L, presenter). Rasagiline improves symptoms in Parkinson's disease (PD) without worsening cognitive and behavioral symptoms. Congress on Mental Dysfunctions in Parkinson's Disease, Salzburg, October 2004.
217. Goetz CG, Schwid SR, Eberly SW, Oakes D, Shoulson I, PSG TEMPO & PRESTO Investigators, et al. Safety of rasagiline in elderly Parkinson's disease (PD) patients. *Mov Disord* 2005;20 (Suppl 10):S81.
218. Parkinson Study Group (de Marcaida, presenter). Rasagiline does not promote tyramine pressor responses. *Mov Disord* 2005; 20 (Suppl 10):S133.
219. Parkinson Study Group (Elmer L, presenter). Rasagiline is effective and well tolerated in the treatment of Parkinson's disease (PD) patients with levodopa-related motor fluctuations receiving other adjunctive therapy. *Mov Disord* 2005;20 (Suppl 10):S138.
220. Kieburtz K, Romer M, McDermott M, Kamp C, Parkinson Study Group. Impact of pramipexole on mood and initiative in early Parkinson's disease. *Mov Disord* 2005;20 (Suppl 10):S121.
221. Parkinson Study Group (Elmer L, presenter). Rasagiline is effective and well tolerated in the treatment of Parkinson's disease (PD) patients with levodopa-related motor fluctuations receiving concomitant dopamine agonist (DA) therapy. *Annals Neurol* 2005;58(Suppl 9):S54.
222. Parkinson Study Group (Schwid SR, presenter). Safety of rasagiline in combination with serotonin reuptake inhibitors. *Annals Neurol* 2005;58(Suppl 9):S56.
223. Parkinson Study Group (Schwid S, presenter). A randomized controlled trial of etilevodopa in Parkinson's disease patients with motor fluctuations. *Mov Disord* 2005;20(9):1237.
224. Pankratz N, Byder L, Halter CA, Rudolph A, Shults CW, Conneally PM, Foroud T, Nichols WC, Parkinson Study Group—PROGENI Investigators. A common non-synonymous SNP in the BR13 (ITM2C) gene accounts for a significant portion of the linkage evidence for Parkinson disease on chromosome 2q. Presented at The American Society of Human Genetics, October 25-29, 2005, Salt Lake City, UT. Available from: <http://www.ashg.org/cgi-bin/ashg05s/ashg05>
225. Constantinescu R, Romer M, Kieburtz K and the DATATOP Parkinson Study Group Investigators. Malignant melanoma in early Parkinson's disease – DATATOP trial. *Mov. Disord* 2006;21(Suppl 13):S120.
226. Parkinson Study Group (Shoulson I, presenter). Baseline comparison of the PRECEPT and DATATOP clinical trial cohorts. *Mov Disord* 2006;21(Suppl 13):S121.
227. Kieburtz K, Romer M, McDermott M, Kamp C and the CALM-PD Parkinson Study Group Investigators. Impact of pramipexole on the onset of levodopa-related dyskinesias. *Mov Disord* 2006;21(Suppl 13):S122.
228. Parkinson Study Group (Tanner CM, presenter). Follow-Up of persons with Neurologic Disease (FOUND): Up to 46 months follow-up. *Mov Disord* 2006;21(Suppl 13):S127.

229. Shoulson I and Parkinson Study Group (PSG) PRECEPT Investigators. CEP-1347 treatment fails to favorably modify the progression of Parkinson's disease (PRECEPT) study. *Neurology* 2006;67(1):185.
230. Parkinson Study Group (Shulman LM, presenter). The POETRY Study: The safety, tolerability and efficacy of estrogen replacement therapy in post-menopausal women with Parkinson's disease. *Mov Disord* 2006;21(9):1545.
231. Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter C, Rudolph A, Shults CW, Foroud T, Nichols WC, Parkinson Study Group—PROGENI Investigators. Mutations in LRRK2 other than G2019S are rare in familial Parkinson disease. Presented at The American Society of Human Genetics, October 9-13, 2006, New Orleans, LA. Available from: <http://www.ashg.org/genetics/ashg/annmeet/2006/call/pdf/2390%20Abstracts,%206-per-page.pdf>, Abstract #2169/B.
232. Nichols WC, Marek DK, Pauciulo MW, Pankratz N, Halter CA, Rudolph A, Shults CW, Wojcieszek J, Foroud T, The Parkinson Study Group—PROGENI Investigators. R1514Q substitution in LRRK2 is not a pathogenic Parkinson disease (PD) mutation. Presented at The American Society of Human Genetics, October 9-13, 2006, New Orleans, LA. Available from: <http://www.ashg.org/genetics/ashg/annmeet/2006/call/pdf/2390%20Abstracts,%206-per-page.pdf>, Abstract #2107/C.
233. Ascherio A, LeWitt PA, Watts A, Kieburtz K, Rudolph A, Schwid SR, Matson WR, Beal MF, LangAE, Oakes D, Fahn S, Shoulson I & Schwarzschild MA on behalf of the PSG DATATOP investigators. (2006) CSF as well as serum urate are predictors of Parkinson's disease progression. Movement Disorders Society International Congress on Parkinson's Disease and Movement Disorders. Kyoto [Abstract #LB-2.]
234. Pankratz N, Halter C, Rudolph A, Shults C, Nichols W, Foroud T, Parkinson Study Group – PROGENI Investigators. Depression in a Cohort of 1335 Individuals with Familial Parkinson Disease. *Neurology* 2007;68(1):A37.
235. Shanker VL, Hailpern SM, Ozelius L, Saunders-Pullman R, Soto-Valencia J, Sethi M, Hunt A, Tagliati M, Groves M, Bressman S. Clinical Expression of the LRRK2 G2019S Mutation in Ashkenazi Jews. *Neurology* 2007;68(1):A324.
236. Biglan KM, Brocht A, McDermott M, Kieburtz K, Parkinson Study Group CALM-PD Investigators. Identifying predictors of somnolence and edema in patients with early Parkinson's disease treated with pramipexole: A secondary analysis of the CALM-PD study. *Mov Disord* 2007;22(16):S231.
237. Biglan KM, Brocht A, McDermott M, Kieburtz K, Parkinson Study Group CALM-PD Investigators. Identifying predictors of response to pramipexole treatment in early Parkinson's disease: A secondary analysis of the CALM-PD study. *Mov Disord* 2007;22(16):S232.
238. Pankratz N, Nichols WC, Elsaesser VE, Pauciulo MW, Marek DK, Halter CA, Rudolph A, Foroud T, Parkinson Study Group—PROGENI Investigators. Dosage changes in alpha-synuclein are rare in familial PD, yet promoter variation is associated with disease. Presented at The American Society of Human Genetics, October 23-27, 2007, San Diego CA. Available from : <http://www.ashg.org/genetics/ashg07s/index.shtml>.

239. Uc EY, McDermott MP, Growdon JC, Marder KS, Anderson SW, Litvan I, Como P, Chou KL, and Parkinson Study Group. Incidence and Predictors of Dementia in Early Parkinson's Disease: Results from the DATATOP Study. *Annals of Neurology* 2008;64(Suppl 12):S2.
240. Uc, EY, McDermott, MP, Weintraub, D, et al. Incidence and Predictors of Depression in Early Parkinson's Disease: Results from the DATATOP study. *Movement Disorders* 2008; 23:873.
241. Shanker VL, Groves M, Hailpern SM, Ozelius LJ, Saunders-Pullman R, Hunt A, Sthi M, Soto-Valencia J, Bressman SB. Mood and anxiety disorders in an Ashkenazi Jewish (AJ) population with LRRK2 G2019S Parkinson's disease. *Mov Disord* 2008;23 (suppl1) 98.
242. Uc EY, McDermott MP, Weintraub D, Marsh L, Growdon J, Chou K, Auinger P, Marder K, Parkinson Study Group. Predictors of depression in early Parkinson's disease. *Neurology* 2009;72:A257-A258.
243. Gao X, Simon KC, Han J, Schwarzschild MA, Ascherio A. family history of melanoma and Parkinson's disease risk. *Neurology* 2009;72(Suppl 3);A490-491.
244. Ravina B, Tanner C, DiEuliis, Flagg E, Shoulson I, Parkinson Study Group LABS-PD Investigators. A longitudinal program for biomarker development in Parkinson's disease. *Mov Disord* 2009;24 S275 (suppl 1).
245. Latourelle JC, Hendricks AE, Wilk JB, DeStefano AL, Pankratz N, Foroud T, Myers RH and the PSG-PROGENI and GenePD Investigators, Coordinators and Molecular Genetic Laboratories. Rare Variants with Recessive Effects Identified in a Genome-wide Association Study of Parkinson's Disease. Annual meeting of the International Epidemiology Society, Kahuku, HI, 2009 Poster #119.
246. Pankratz N, Dumitriu A, Latourelle JC, Wilk JB, DeStefano AL, Hetrick KN, Myers RH, Foroud T, the PSG-PROGENI and GenePD Investigators, Coordinators and Molecular Genetic Laboratories. Which CNV analysis strategies can identify a well-known disease causing CNV? Platform presentation (#302).
247. Latourelle JC, Pankratz N, Hendricks AE, Wilk JB, DeStefano AL, Foroud T, Myers RH, the PSG-PROGENI and GenePD Investigators, Coordinators and Molecular Genetic Laboratories. Genomewide Linkage and Association Study of Onset Age of LRRK2-related Parkinson's Disease. Poster presentation (#1864).
248. Marder KS, Clark LN, McDermott M, Uc E, and PSG DATATOP Investigators. Genetic Risk Factors for Cognitive Impairment in the DATATOP Cohort. Accepted for a poster presentation at the AAN 2010 meeting in Toronto, Canada.
249. Huang X, Auinger P, Eberly S, Oakes D, Schwarzschild M, Ascherio A, Mailman R, Chen H, for the Parkinson Study Group DATATOP Investigators. Serum Cholesterol as a Predictor of the Rate of Clinical Decline in Parkinson Disease: Results from DATATOP. Accepted for a platform presentation at the 24th Annual PSG Symposium. May 2010.
250. Paumier KL, Siderowf A, Auinger P, Oakes D, Espay AJ, Revilla FJ, Sahay A, Collier TJ. Treatment with antidepressants delays progression of disability in early Parkinson's disease. Accepted for a platform presentation at the 24th Annual PSG Symposium, May 2010.

251. Marek K, Ravina B, Seibyl J, Jennings D, Eberly S, Oakes D, Shoulson I, for the PSG PostCEPT (LABS-PD) Investigators. Dopamine Transporter (DAT) Imaging Predicts Motor and Treatment-Resistant Outcomes in Parkinson Disease. Accepted for a platform presentation at the 24th Annual PSG Symposium, May 2010.
252. Uc EY, Papapetropoulos S, Auinger P, Singer C, Marder KS, Clark LN, McDermott MP, Oakes D, and Investigators for DATATOP, CALM-PD, PRESTO studies of the Parkinson Study Group. Weight Loss in Parkinson's Disease across Different Stages. This abstract was accepted for a poster presentation at the MDS 14th International Congress of PD and Movement Disorders, June 2010 in Buenos Aires and will be published in *Movement Disorders*.
253. Peterson AL, Quinn JF, Horak FB, Nutt JG. The Relationship Between Balance, as Measured by Clinical Posturography, and Vitamin D in Parkinson's Disease. This abstract was accepted for a poster presentation at the MDS 14th International Congress of PD and Movement Disorders, June 2010 in Buenos Aires and will be published in *Movement Disorders*.

ANCILLARY STUDIES

1. Cronin-Golomb A, Corkin S, Growdon JH. Impaired problem solving in Parkinson's disease: impact of a set-shifting deficit. *Neuropsychologia* 1994; 32:579-593.

PSG ANNUAL SYMPOSIA

1. Shoulson I, Fahn S, Langston JW. Symposium on the Etiology, Pathogenesis, and Prevention of Parkinson's Disease. *Arch Neurol* 1988;45:807-811.
2. Second Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Symposium on Hyperkinetic Movement Disorders. Co-sponsored by the Parkinson Study Group and The *Movement* Disorder Society. *Arch Neurol* 1988;45:807-811.
3. Third Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Symposium on Hyperkinetic Movement Disorders. Co-sponsored by the Parkinson Study Group and The *Movement* Disorder Society. September 24, 1989 (New Orleans, Louisiana).
4. Fourth Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Symposium on Hyperkinetic Movement Disorders. Co-sponsored by the Parkinson Study Group and The *Movement* Disorder Society. *Ann Neurol* 1990;28(2):294-301.
5. Fifth Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Symposium on Hyperkinetic Movement Disorders. Co-sponsored by the Parkinson Study Group and The *Movement* Disorder Society. *Mov Disord* 1991;6(3):269-272.
6. Sixth Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Symposium on Hyperkinetic Movement Disorders. Co-sponsored by the Parkinson Study Group and The *Movement* Disorder Society. *Mov Disord* 1992;7(5):288-295
7. Seventh Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Symposium on Hyperkinetic Movement Disorders. Co-sponsored by the Parkinson Study Group and The *Movement* Disorder Society. *Mov Disord* 1993;8(3):403-411.
8. Eighth Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Symposium on Hyperkinetic Movement Disorders. Co-sponsored by the Parkinson Study Group and The *Movement* Disorder Society. *Mov Disord* 1994;9(4):474-486.
9. Ninth Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Symposium on Hyperkinetic Movement Disorders. Co-sponsored by the Parkinson Study Group and The *Movement* Disorder Society. *Mov Disord* 1995;10(5):688-695.
10. Tenth Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Symposium on Hyperkinetic Movement Disorders. Co-sponsored by the Parkinson Study Group and The *Movement* Disorder Society. *Mov Disord* 1996;11(5):592-609.

11. Eleventh Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Symposium on Hyperkinetic Movement Disorders. Co-sponsored by the Parkinson Study Group and The *Movement* Disorder Society. *Mov Disord* 1997;12(5):833-847.
12. Twelfth Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Symposium on Etiology, Pathogenesis and Treatment of Huntington's Disease. Co-sponsored by the Parkinson Study Group, Huntington Study Group and The *Movement* Disorder Society. *Mov Disord* 1998;13(5):858-863.
13. Thirteenth Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders. Co-sponsored by the Parkinson Study Group, Huntington Study Group, Cooperative Ataxia Group, Dystonia Study Group, Myoclonus Study Group, Tourette's Syndrome Study Group and The *Movement* Disorder Society. *Mov Disord* 1999;14(5):898-909.
14. Fourteenth Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders. Co-sponsored by the Parkinson Study Group, Huntington Study Group, Cooperative Ataxia Group, Dystonia Study Group, Myoclonus Study Group, Tourette's Syndrome Study Group and The *Movement* Disorder Society. *Mov Disord* 2000;15(5):1038-1048.
15. Fifteenth Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders. Co-sponsored by the Parkinson Study Group, Huntington Study Group, Cooperative Ataxia Group, Dystonia Study Group, Myoclonus Study Group, Tourette's Syndrome Study Group and The *Movement* Disorder Society. *Mov Disord* 2001;15(5):981-994.
16. Sixteenth Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders. Co-sponsored by the Parkinson Study Group, Huntington Study Group, Cooperative Ataxia Group, Dystonia Study Group, Myoclonus Study Group, Tourette's Syndrome Study Group and The *Movement* Disorder Society. *Mov Disord* 2002;17(5):1103-1114.
17. Seventeenth Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders. Co-sponsored by the Parkinson Study Group, Huntington Study Group, Cooperative Ataxia Group, Dystonia Study Group, Myoclonus Study Group, Tourette's Syndrome Study Group and The *Movement* Disorder Society. *Mov Disord* 2003;18(9):1082-1095.
18. Eighteenth Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders. Co-sponsored by the Parkinson Study Group, Huntington Study Group, Cooperative Ataxia Group, Dystonia Study Group, Myoclonus Study Group, Tourette's Syndrome Study Group Tremor Research Group and The *Movement* Disorder Society. *Mov Disord* 2004;19(9):1118-1134.
19. Nineteenth Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders. Co-sponsored by the Parkinson Study Group, Huntington Study Group, Dystonia Study Group, Myoclonus Study Group, Tourette's

- Syndrome Study Group, Cooperative Ataxia Group, Tremor Research Group and The *Movement Disorder Society* under the Auspices of the American Neurological Association. *Mov Disord* 2005;20(9):1235-1249.
20. Twentieth Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders. Co-sponsored by the Parkinson Study Group, Huntington Study Group, Dystonia Study Group, Myoclonus Study Group, Tourette's Syndrome Study Group, Cooperative Ataxia Group, Tremor Research Group and The *Movement Disorder Society* under the Auspices of the American Neurological Association. *Mov Disord* 2006;21(9):1543-1559.
 21. Twenty First Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders. Co-sponsored by the Parkinson Study Group, Huntington Study Group, Dystonia Study Group, Myoclonus Study Group, Tourette's Syndrome Study Group, Cooperative Ataxia Group, Tremor Research Group and The *Movement Disorder Society* under the Auspices of the American Neurological Association. *Mov Disord* 2007;22(12):I-XVI.
 22. Twenty Second Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders. Co-sponsored by the Parkinson Study Group, Huntington Study Group, Dystonia Study Group, Myoclonus Study Group, Tourette's Syndrome Study Group, Cooperative Ataxia Group, Tremor Research Group and The *Movement Disorder Society* under the Auspices of the American Neurological Association. *Mov Disord* 2008;23(11):1628-1637.
 23. Twenty Third Annual Symposium on Etiology, Pathogenesis and Treatment of Parkinson's Disease and Other Movement Disorders. Presented by the Parkinson Study Group, Huntington Study Group, Dystonia Study Group, Myoclonus Study Group, Tourette's Syndrome Study Group, Cooperative Ataxia Group, and Tremor Research Group under the auspices of the American Neurological Association. *Mov Disord* 2009;24(12):1870-1880.

